Triclabendazole progress report, 2005-2009: an advancement of learning?
Triclabendazole progress report, 2005-2009: an advancement of learning?
复制标题
DOI：
10.1017/s0022149x09321173
复制
发表时间：
2009-06-01
影响因子：
1.6
通讯作者：
Fairweather, I.
中科院分区：
文献类型：
--
作者：
Fairweather, I.
三氯苯达唑（TCBZ）仍然是治疗家畜肝片吸虫感染的首选药物，也已成为治疗人类肝片吸虫病的主要药物。继续有报告称牲畜出现抗药性病例，表明这一问题正在加剧。为了解决这一问题，有必要更好地了解毒品的作用。本作者于2005年发表了一份关于透明度和能力建设区活动不同方面的“现状”审查报告。本综述的主要目的是评估过去四年在了解药物活性的主要方面（包括药物药代动力学和药效学）以及了解耐药机制方面取得的进展。此外，在确定替代化合物和使用药物组合来增强TCBZ活性方面取得了哪些进展。源于一些体内研究，很明显，不同敏感性TCBZ的吸虫分离株不同，在他们的一些生物学参数，并将介绍这一有趣的现象的信息。还提供了TCBZ用于人类片形吸虫病的最新情况。审查将表明取得了哪些进展，但也将突出仍然没有得到充分了解和需要更多研究重点的领域。
Triclabendazole (TCBZ) remains the drug of choice for treating infections of the liver fluke, Fasciola hepatica in livestock and has become the main drug used to treat human cases of the disease as well. Cases of resistance in livestock continue to be reported, suggesting that the problem is increasing. In order to address the problem, there is a need for better understanding of drug action. A 'state-of-play' review on different aspects of TCBZ activity was published by the present author in 2005. The main purpose of the current review is to assess what progress has been made in the past four years towards understanding the main aspects of drug activity, including drug pharmacokinetics and pharmacodynamics and an understanding of the mechanism(s) of resistance. Also, what advances have been made in identifying alternative compounds and using drug combinations to enhance TCBZ activity. Stemming from a number of in vivo studies, it has become evident that fluke isolates of differing sensitivity to TCBZ differ in some of their biological parameters, and information on this interesting phenomenon will be presented. An update on the use of TCBZ for human fascioliasis is also given. The review will indicate what progress has been made, but will also highlight areas that remain inadequately understood and require greater research focus.